Ash Stevens gets FDA nod for ixazomib production; Anderson appointed CMO at Symbiosis; Idera inks deal with GSK;

> The FDA has given Ash Stevens ($ASI) the go ahead to begin manufacturing the API ixazomib, an oral proteasome inhibitor used to treat multiple myeloma, at the company's Riverview, MI, facility. Story

> Symbiosis Pharmaceutical Services has appointed Joanne Anderson at its new business development director. Release

> Idera Pharmaceuticals ($IDRA) has entered into a $100 million collaboration and license agreement with GlaxoSmithKline ($GSK) to research, develop and commercialize for the treatment of renal disease. Story